Compounding Pharmacy Recalls Sterile Products Over Sterility Concerns
Ethan Kowalski · Performance Science Writer
November 22, 2026 · 1 min read
Greenwich Rx, a 503A compounding pharmacy based in Tomball, Texas, is voluntarily recalling specific lots of compounded sterile products that remain within their beyond use dates, according to an FDA recall notice. The recall also covers products Greenwich Rx compounded on behalf of another pharmacy, Clove Rx. Affected items were dispensed nationwide between August 10, 2026 and September 21, 2026.
The company says the recall follows an FDA inspection of its facility and its own subsequent evaluation of the products in question. Greenwich Rx states it has not identified evidence of contamination and has received no adverse event reports tied to the recall, but it is acting as a precaution because a lack of sterility assurance in a product meant to be sterile could lead to serious, potentially life threatening infections.
Customers of either pharmacy are advised to check their medication labels against the lot list posted on Greenwich Rx's site and to stop using any affected product immediately. Those who received medications through Clove Rx are encouraged to check the list even without a direct notice. This episode is a reminder that compounded sterile products, including injectable formulations sometimes used in peptide research contexts, depend heavily on pharmacy quality controls that regulators continue to monitor closely.
This article is for education only. It is not medical advice. Compounds discussed here are sold for research purposes. Talk to a licensed clinician before making health decisions.
Ready to explore peptides?
Browse every compound profile or work out your dose with the reconstitution calculator.


